{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:37:57Z","timestamp":1790656677221,"version":"4.1.0"},"reference-count":52,"publisher":"American Academy of Insurance Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title\/>\n<jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative disorder in which there is a neoplastic proliferation of mature granulocytes. The cancer results from a reciprocal translocation of the breakpoint cluster region (BCR) on chromosome 22 and the ABL1 gene region on chromosome 9 - t (9;22). The result is an abnormal fusion gene on chromosome 22 known as the Philadelphia chromosome. It represents 15% to 20% of all leukemias in the United States with an estimated incidence rate of 1 to 2 cases per 100,000. About 50% of affected individuals are asymptomatic.<\/jats:p>\n<jats:p>Diagnosis depends on demonstrating the presence of the Philadelphia chromosome. CML occurs in 3 phases. The most common is the chronic phase characterized by an indolent course and &lt;15% blast cells in the myeloid space. The remaining advanced phases are the accelerated (15%-30% blasts) and the blast phase (&gt;30% blasts). Without treatment, progression is slow but relentless to the advanced stages and occurs over 3 to 5 years. Survival is markedly reduced once these latter stages are reached. The recognition that the BCR-ABL1 fusion gene was a key driver of the disease process led to the development of tyrosine kinase inhibitor (TKI) drugs that targeted the genetic basis for the cancer. The first of these was imatinib, which was released in 2001. Since then both second and third generations of the drug class have been approved. These medications have been demonstrated to reduce the ratio of abnormal to normal BCR:ABL1 transcripts. They are most effective if used in the chronic phase. The degree of this molecular response has been demonstrated to correlate with limitation of progression of disease and improvement, often marked, of survival. Most individuals who respond well require lifelong use of the medication. However, a subset of the responders may achieve treatment-free remission (TFR) without ongoing therapy. For those individuals who are in the advanced state of the disease, do not respond to the TKI drugs or cannot tolerate them, allogeneic hematopoietic stem cell transplantation (SCT) is an alternative therapy that can achieve long-term survival in some cases.<\/jats:p>","DOI":"10.17849\/insm-52-3-1-7.2","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T02:46:07Z","timestamp":1757990767000},"page":"137-143","source":"Crossref","is-referenced-by-count":7,"title":["Chronic Myeloid Leukemia \u2013 A Review of Current Status"],"prefix":"10.17849","volume":"52","author":[{"given":"Clifton P.","family":"Titcomb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7324","reference":[{"key":"i-52-3-137-ref01","article-title":"Clinical Manifestations and Diagnosis of Chronic Myeloid Leukemia","author":"Van Etten","unstructured":"Van Etten RA. Clinical Manifestations and Diagnosis of Chronic Myeloid Leukemia. \nLarson RA,\nRosmarin AG, eds. UpToDate. Waltham, MA: UpToDate Inc. http:\/\/www.uptodate.com (Accessed on November 7, 2024.)"},{"issue":"5","key":"i-52-3-137-ref02","series-title":"HemaSphere","first-page":"e468","article-title":"Chronic Myeloid Leukemia in 2020","volume":"4","author":"Hehlmann","year":"2020","unstructured":"Hehlmann R. Chronic Myeloid Leukemia in 2020. HemaSphere. 2020;4:5(e468). http:\/\/dx.doi.org\/10.1097\/"},{"key":"i-52-3-137-ref03","author":"Cancer Stat Facts: Leukemia","unstructured":"Cancer Stat Facts: Leukemia. https:\/\/seer.gove\/statfacts\/cmyl\/html"},{"key":"i-52-3-137-ref04","article-title":"Key Statistics for Chronic Myeloid Leukemia","author":"American Cancer Society","unstructured":"American Cancer Society: Key Statistics for Chronic Myeloid Leukemia, https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/about\/statistics.html"},{"key":"i-52-3-137-ref05","series-title":"JCO Global Oncol","first-page":"1429","article-title":"Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019","volume":"7","author":"Hu","year":"2021","unstructured":"Hu Y,\nLi Q,\nHou M, et al. Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019. JCO Global Oncol. 2021;7:1429\u20131441."},{"key":"i-52-3-137-ref06","article-title":"Risk Factors for Chronic Myeloid Leukemia","author":"American Cancer Society","unstructured":"American Cancer Society; Risk Factors for Chronic Myeloid Leukemia, https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/causes-risks-prevention\/risk-factors.html"},{"key":"i-52-3-137-ref07","series-title":"Am J Hematol","first-page":"2191","article-title":"Chronic Myeloid Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring","volume":"99","author":"Jabour","year":"2024","unstructured":"Jabour E,\nKantarjian H. Chronic Myeloid Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring. Am J Hematol. 2024;99:2191\u20132212."},{"key":"i-52-3-137-ref08","article-title":"Overview of Treatment of Chronic Myeloid Leukemia","author":"Schiffer","unstructured":"Schiffer CA. Overview of Treatment of Chronic Myeloid Leukemia. \nLarson RA,\nRosmarin AG, eds. UpToDate. Waltham, MA: UpToDate Inc. http:\/\/www.uptodate.com (Accessed on November 7, 2024.)"},{"key":"i-52-3-137-ref09","series-title":"Korean J Fam Med","first-page":"197","article-title":"An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians","volume":"36","author":"Granatowicz","year":"2015","unstructured":"Granatowicz A,\nPlatek CI,\nMoschiano E, et al. An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean J Fam Med. 2015;36:197\u2013201."},{"key":"i-52-3-137-ref10","article-title":"CML Phases and Prognostic Factors","author":"Leukemia & Lymphoma Society","unstructured":"Leukemia & Lymphoma Society. CML Phases and Prognostic Factors. https:\/\/www.lls.org\/leukemia\/chronic-myeloid-leukemia\/diagnosis\/cml-phases-and-prognostic-factors"},{"key":"i-52-3-137-ref11","series-title":"Leukemia","first-page":"48","article-title":"Prognosis of Long-Term Survival Considering Disease-Specific Death in Patients with Chronic Myeloid Leukemia","volume":"30","author":"Pfirrmann","year":"2016","unstructured":"Pfirrmann M,\nCaccarani M,\nSaussele S, et al. Prognosis of Long-Term Survival Considering Disease-Specific Death in Patients with Chronic Myeloid Leukemia. Leukemia. 2016;30:48\u201356."},{"key":"i-52-3-137-ref12","series-title":"Blood Cancer J","first-page":"58","article-title":"Management of Chronic Myeloid Leukemia in 2023 \u2013 Common Ground and Common Sense","volume":"13","author":"Senapati","year":"2023","unstructured":"Senapati J,\nSasaki K,\nIssa GC, et al. Management of Chronic Myeloid Leukemia in 2023 \u2013 Common Ground and Common Sense. Blood Cancer J. 2023;13:58. https:\/\/doi.org\/10.1038\/s41408-023-00823-9"},{"key":"i-52-3-137-ref13","series-title":"Blood Res","first-page":"S109","article-title":"Treatment After Failure of Frontline therapy of Chronic Myeloid Leukemia in Chronic Phase Including Allogeneic Hematopoietic Stem Cell Transplantation","volume":"58","author":"Uhm","year":"2023","unstructured":"Uhm J. Treatment After Failure of Frontline therapy of Chronic Myeloid Leukemia in Chronic Phase Including Allogeneic Hematopoietic Stem Cell Transplantation. Blood Res. 2023;58:S109\u2013S113."},{"issue":"6","key":"i-52-3-137-ref14","series-title":"Blood Cancer J","first-page":"94","article-title":"Outcomes and Patterns of Treatment in Chronic Myeloid Leukemia, A Global Perspective Based on Real-World Data Global Network","volume":"12","author":"Sanz","year":"2022","unstructured":"Sanz A,\nAyala R,\nHern\u00e1ndez G, et al. Outcomes and Patterns of Treatment in Chronic Myeloid Leukemia, A Global Perspective Based on Real-World Data Global Network. Blood Cancer J. 2022;12(6):94. doi:10.1038\/s41408-022-00692-8"},{"key":"i-52-3-137-ref15","series-title":"Cancers","first-page":"2521","article-title":"Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo with CP-CML Patients","volume":"12","author":"Etienne","year":"2020","unstructured":"Etienne G,\nDulucq S,\nBauduer F, et al. Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo with CP-CML Patients. Cancers. 2020;12:2521. doi:10.3390\/cancers12092521"},{"key":"i-52-3-137-ref16","series-title":"J Clin Oncol","first-page":"415","article-title":"Deep Molecular Response is Reached by the Majority of Patients Treated with Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the CML-Study IV","volume":"32","author":"Hehlmann","year":"2013","unstructured":"Hehlmann R,\nMuller MC. Deep Molecular Response is Reached by the Majority of Patients Treated with Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the CML-Study IV. J Clin Oncol. 2013;32:415\u2013423."},{"key":"i-52-3-137-ref17","series-title":"Leuk Lymphoma","first-page":"2213","article-title":"Long-Term Outcomes of Patients with Chronic Myeloid Leukemia Who Commenced Treatment with Imatinib: A 20-Year Single-Centre Experience","volume":"63","author":"Szczepanek","year":"2022","unstructured":"Szczepanek E,\nChukwu O,\nKami\u0144ska M, et al. Long-Term Outcomes of Patients with Chronic Myeloid Leukemia Who Commenced Treatment with Imatinib: A 20-Year Single-Centre Experience. Leuk Lymphoma. 2022;63:2213\u20132223."},{"key":"i-52-3-137-ref18","series-title":"Curr Hematol Malig Rep","first-page":"415","article-title":"Chronic Myeloid Leukemia \u2013 The Promise of Tyrosine Kinase Inhibitor Discontinuation","volume":"12","author":"Narra","year":"2017","unstructured":"Narra RK,\nFlynn KE,\nAtallah E. Chronic Myeloid Leukemia \u2013 The Promise of Tyrosine Kinase Inhibitor Discontinuation. Curr Hematol Malig Rep. 2017;12:415\u2013423."},{"key":"i-52-3-137-ref19","series-title":"Ulster Med J","first-page":"105","article-title":"Response to Therapy, Treatment Intolerance, and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real -World Cohort of chronic Myeloid Leukaemia Patients","volume":"88","author":"McMullan,","year":"2019","unstructured":"McMullan,\nMcConville C,\nMcMullan MF. Response to Therapy, Treatment Intolerance, and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real -World Cohort of chronic Myeloid Leukaemia Patients. Ulster Med J. 2019;88:105\u2013110."},{"key":"i-52-3-137-ref020","series-title":"Blood Adv","first-page":"3034","article-title":"Late Molecular Recurrences in Patients with Chronic Myeloid Leukemia Experiencing Treatment-Free Remission","volume":"4","author":"Rousselot","year":"2020","unstructured":"Rousselot P,\nLoiseau C,\nLoiseau C,\nDelord M,\nCayuela JM,\nSpentchian M. Late Molecular Recurrences in Patients with Chronic Myeloid Leukemia Experiencing Treatment-Free Remission. Blood Adv. 2020;4:3034\u20133040."},{"key":"i-52-3-137-ref021","series-title":"Leukemia","first-page":"966","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","unstructured":"Hochhaus A,\nBaccarani M,\nSilver RT, et al. European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia. Leukemia. 2020;34:966\u2013984."},{"key":"i-52-3-137-ref022","series-title":"Cancer","first-page":"2620","article-title":"Trends in All-Cause Mortality Among Patients with Chronic Myeloid Leukemia: A Surveillance, Epidemiology, and End Results Database Analysis","volume":"119","author":"Brunner","year":"2013","unstructured":"Brunner AM,\nCampigotto F,\nSadrzadeh H, et al. Trends in All-Cause Mortality Among Patients with Chronic Myeloid Leukemia: A Surveillance, Epidemiology, and End Results Database Analysis. Cancer. 2013;119:2620\u20132629."},{"key":"i-52-3-137-ref023","series-title":"Cancer","first-page":"3805","article-title":"Outcome of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the United States Since the Introduction of Imatinib Therapy \u2013 The Surveillance, Epidemiology, and End Results Database, 2000\u20132019","author":"Sasaki","year":"2023","unstructured":"Sasaki K,\nHaddad,\nShort NJ, et al. Outcome of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the United States Since the Introduction of Imatinib Therapy \u2013 The Surveillance, Epidemiology, and End Results Database, 2000\u20132019. Cancer. 2023;3805\u20133814."},{"key":"i-52-3-137-ref024","series-title":"Eur J Haematol","first-page":"145","article-title":"Chronic Myeloid Leukemia in the Netherlands: A Population-Based Study on Incidence, Treatment, and Survival in 3585 Patients from 1989 to 2012","volume":"97","author":"Thielen","year":"2015","unstructured":"Thielen N,\nVisser O,\nOssenkoppele G,\nJanssen J. Chronic Myeloid Leukemia in the Netherlands: A Population-Based Study on Incidence, Treatment, and Survival in 3585 Patients from 1989 to 2012. Eur J Haematol. 2015;97:145\u2013154."},{"key":"i-52-3-137-ref025","series-title":"Leukemia","first-page":"3291","article-title":"Conditional Relative Survival Among Adult Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A Population-Based Study in the Netherlands","volume":"35","author":"Ector","year":"2021","unstructured":"Ector GICG,\nVisser O,\nPosthuma E, et al. Conditional Relative Survival Among Adult Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A Population-Based Study in the Netherlands. Leukemia. 2021;35:3291\u20133294."},{"key":"i-52-3-137-ref026","series-title":"N Engl J Med","first-page":"917","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","unstructured":"Hochhaus A,\nLarson RA,\nGuilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917\u2013927."},{"key":"i-52-3-137-ref027","series-title":"J Natl Cancer Inst","first-page":"553","article-title":"Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated with Imatinib","volume":"103","author":"Gambacorti-Passarini","year":"2011","unstructured":"Gambacorti-Passarini C,\nAntolini L,\nMahon FX, et al. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated with Imatinib. J Natl Cancer Inst. 2011;103:553\u2013561."},{"key":"i-52-3-137-ref028","series-title":"Front Oncol","article-title":"Long-Term Outcomes of Frontline Imatinib Therapy for Chronic Myeloid Leukemia in China","volume":"13","author":"Cheng","year":"1172","unstructured":"Cheng F,\nYuan G,\nLi Q, et al. Long-Term Outcomes of Frontline Imatinib Therapy for Chronic Myeloid Leukemia in China. Front Oncol. 13:1172910. doi:10.3389\/fonc.2023.1172910"},{"key":"i-52-3-137-ref029","series-title":"Lancet Haematol","first-page":"e186","article-title":"Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors","volume":"2","author":"Sasaki","year":"2015","unstructured":"Sasaki K,\nStrom SS,\nO\u2019Brien S, et al. Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors. Lancet Haematol. 2015;2:e186\u2013e193."},{"key":"i-52-3-137-ref030","series-title":"Cancer","first-page":"238","article-title":"Conditional Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors","volume":"122","author":"Sasaki","year":"2016","unstructured":"Sasaki K,\nKantarjian HM,\nJain P, et al. Conditional Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors. Cancer. 2016;122:238\u2013248."},{"key":"i-52-3-137-ref031","series-title":"Leukemia","first-page":"2231","article-title":"Survival with Chronic Myeloid Leukemia After Failing Milestones","volume":"37","author":"Lauseker","year":"2023","unstructured":"Lauseker M,\nHehlmann,\nHochhaus A, et al. Survival with Chronic Myeloid Leukemia After Failing Milestones. Leukemia. 2023;37:2231\u20132236."},{"key":"i-52-3-137-ref032","series-title":"Ann Hematol","first-page":"1891","article-title":"Ten-Year Outcome of Chronic-Phase Myeloid Leukemia Patients with Imatinib in Real Life","volume":"98","author":"Molica","year":"2019","unstructured":"Molica M,\nColafigli G,\nScalzulli E, et al. Ten-Year Outcome of Chronic-Phase Myeloid Leukemia Patients with Imatinib in Real Life. Ann Hematol. 2019;98:1891\u20131904."},{"key":"i-52-3-137-ref033","series-title":"Acta Haematol","first-page":"298","article-title":"Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature","volume":"132","author":"Pemmaraju","year":"2014","unstructured":"Pemmaraju N,\nCortes J. Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature. Acta Haematol. 2014;132:298\u2013306."},{"key":"i-52-3-137-ref034","series-title":"Eur J Haematol","article-title":"Clinical Results According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, Worse","author":"Latagliata","year":"2018","unstructured":"Latagliata R,\nBreccia,\nCarmosino I, et al. Clinical Results According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, Worse? Eur J Haematol. 2018 Jun 13. doi:10.1111\/ejh.13110. Online ahead of print."},{"key":"i-52-3-137-ref035","series-title":"Ann Hematol","first-page":"71","article-title":"Younger Patients with Chronic Myeloid Leukemia Do Well in Spite of Poor Prognostic Indicators: Results from the Randomized CML Study IV","volume":"93","author":"Kalmanti","year":"2014","unstructured":"Kalmanti L,\nSaussele S, et al. Younger Patients with Chronic Myeloid Leukemia Do Well in Spite of Poor Prognostic Indicators: Results from the Randomized CML Study IV. Ann Hematol. 2014;93:71\u201380."},{"key":"i-52-3-137-ref036","series-title":"Ann of Med","first-page":"1244","article-title":"Outcomes of Adolescents and Young Adults with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors","volume":"54","author":"Nishiyama-Fujita","year":"2022","unstructured":"Nishiyama-Fujita Y,\nNakazato T,\nIriyama N, et al. Outcomes of Adolescents and Young Adults with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. Ann of Med. 2022;54:1244\u20131254."},{"key":"i-52-3-137-ref037","series-title":"Ann Oncol","first-page":"185","article-title":"Differences Among Young Adults, Adults and Elderly Chronic Myeloid Leukemia Patients","volume":"26","author":"Castagnetti","year":"2015","unstructured":"Castagnetti F,\nGugliotta G,\nBaccarani M, et al. Differences Among Young Adults, Adults and Elderly Chronic Myeloid Leukemia Patients. Ann Oncol. 2015;26:185\u2013192."},{"key":"i-52-3-137-ref038","series-title":"J Clin Oncol","first-page":"2851","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","unstructured":"Bower H,\nBjorkholm M,\nDickman PW, et al. Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34:2851\u20132857."},{"key":"i-52-3-137-ref039","series-title":"Br J Hematol","first-page":"1219","article-title":"The Evolution of the Loss of Life Expectancy in Patients with Chronic Myeloid Leukemia: A Population-Based Study in the Netherlands, 1989\u20132018","volume":"196","author":"Maas","year":"2022","unstructured":"Maas CCHM,\nvan Klaveren D,\nEctor GICG, et al. The Evolution of the Loss of Life Expectancy in Patients with Chronic Myeloid Leukemia: A Population-Based Study in the Netherlands, 1989\u20132018. Br J Hematol. 2022;196:1219\u20131224."},{"key":"i-52-3-137-ref040","series-title":"Leukemia","first-page":"333","article-title":"Do Persons with Chronic Myeloid Leukemia Have Normal or near Normal Survival","volume":"34","author":"Radivoyevitch","year":"2020","unstructured":"Radivoyevitch T,\nWeaver D,\nHobbs B, et al. Do Persons with Chronic Myeloid Leukemia Have Normal or near Normal Survival? Leukemia. 2020;34:333\u2013335."},{"key":"i-52-3-137-ref041","series-title":"Am J Hematol","first-page":"1236","article-title":"Prognosis of Patients with Chronic Myeloid Leukemia Presenting in Advanced Phase is Defined Mainly by Blast Count, But Also Age, Chromosomal Aberrations and Hemoglobin","volume":"94","author":"Lauseker","year":"2019","unstructured":"Lauseker M,\nBachl K,\nTurkina A, et al. Prognosis of Patients with Chronic Myeloid Leukemia Presenting in Advanced Phase is Defined Mainly by Blast Count, But Also Age, Chromosomal Aberrations and Hemoglobin. Am J Hematol. 2019;94:1236\u20131243."},{"key":"i-52-3-137-ref042","series-title":"Cancer","first-page":"4391","article-title":"Prognostic Factors and Survival Outcomes in Patients with Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients","volume":"123","author":"Jain","year":"2017","unstructured":"Jain P,\nKantarjian HM,\nGhorab A, et al. Prognostic Factors and Survival Outcomes in Patients with Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients. Cancer. 2017;123:4391\u20134402."},{"key":"i-52-3-137-ref043","series-title":"J Clin Oncol","first-page":"1888","article-title":"Relapse and Late Morality in 5-Year Survivor s of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase","volume":"28","author":"Goldman","year":"2010","unstructured":"Goldman JM,\nMajhail NS,\nSandin F, et al. Relapse and Late Morality in 5-Year Survivor s of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase. J Clin Oncol. 2010;28:1888\u20131895."},{"key":"i-52-3-137-ref044","series-title":"Bone Marrow Transplant","first-page":"1764","article-title":"Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia in the TKI Era: Population-Based Data from the Swedish CML Registry","volume":"54","author":"Lubking","year":"2019","unstructured":"Lubking A,\nDreimane A, et al. Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia in the TKI Era: Population-Based Data from the Swedish CML Registry. Bone Marrow Transplant. 2019;54:1764\u20131774."},{"key":"i-52-3-137-ref045","series-title":"Leukemia","first-page":"562","article-title":"Long-Term Outcome of Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Randomized Comparison of Stem Cell Transplantation with Drug Treatment","volume":"30","author":"Gratwohl","year":"2016","unstructured":"Gratwohl A,\nPfirrmann M,\nZanderr A, et al. Long-Term Outcome of Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Randomized Comparison of Stem Cell Transplantation with Drug Treatment. Leukemia. 2016;30:562\u2013569."},{"key":"i-52-3-137-ref046","series-title":"eJHaem","first-page":"117","article-title":"Allogeneic Stem Cell Transplant Recipients Surviving At Least 2 Years Without Relapse: Outcome and Risk Factors","volume":"5","author":"Gronvold","year":"2024","unstructured":"Gronvold BL,\nAli MM,\nMyklebust TA, et al. Allogeneic Stem Cell Transplant Recipients Surviving At Least 2 Years Without Relapse: Outcome and Risk Factors. eJHaem. 2024;5:117\u2013124."},{"key":"i-52-3-137-ref047","series-title":"Blood","first-page":"1880","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation (allo SCT) for Chronic Myeloid Leukemia in the Imatinib Era: Evaluation of Its Impact Withing a Subgroup of the Randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","unstructured":"Saussele S,\nLauseker M,\nGratwohl A, et al. Allogeneic Hematopoietic Stem Cell Transplantation (allo SCT) for Chronic Myeloid Leukemia in the Imatinib Era: Evaluation of Its Impact Withing a Subgroup of the Randomized German CML Study IV. Blood. 2010;115:1880\u20131885."},{"key":"i-52-3-137-ref048","series-title":"Cancer","first-page":"4033","article-title":"Late Mortality After Bone Marrow Transplant for Chronic Myelogenous Leukemia in the Context of Prior Tyrosine Kinase Inhibitor Exposure: A Bloor or Marrow Transplant Survivor Study (BMTSS) Report","volume":"125","author":"Wu","year":"2019","unstructured":"Wu J,\nChen Y,\nHageman L, et al. Late Mortality After Bone Marrow Transplant for Chronic Myelogenous Leukemia in the Context of Prior Tyrosine Kinase Inhibitor Exposure: A Bloor or Marrow Transplant Survivor Study (BMTSS) Report. Cancer. 2019;125:4033\u20134022."},{"issue":"1","key":"i-52-3-137-ref049","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"177","article-title":"We Do Still Transplant CML, Don\u2019t We","volume":"2018","author":"Craddock","year":"2018","unstructured":"Craddock CF. We Do Still Transplant CML, Don\u2019t We? Hematology Am Soc Hematol Educ Program. 2018;2018(1):177\u2013184."},{"key":"i-52-3-137-ref050","series-title":"Bone Marrow Transplant","first-page":"2834","article-title":"Risk Factors for Outcome After Allogeneic Stem Cell Transplantation in Patients with Advanced Phase CML","volume":"56","author":"Niederwieser","year":"2021","unstructured":"Niederwieser C,\nMorozova E,\nZubarovskaya L, et al. Risk Factors for Outcome After Allogeneic Stem Cell Transplantation in Patients with Advanced Phase CML. Bone Marrow Transplant. 2021;56:2834\u20132841."},{"key":"i-52-3-137-ref051","series-title":"Clin Cancer Res","first-page":"2020","article-title":"Impact of Chronic Graft-Versus-Host Disease on Late Relapse and Survival on 7489 Patients After Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia","volume":"21","author":"Boyiadzis","year":"2015","unstructured":"Boyiadzis M,\nArora M,\nKlein JP, et al. Impact of Chronic Graft-Versus-Host Disease on Late Relapse and Survival on 7489 Patients After Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015;21:2020\u20132028."},{"key":"i-52-3-137-ref052","series-title":"Front Oncol","first-page":"722507","article-title":"Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches","volume":"11","author":"Diamantopoulos","year":"2021","unstructured":"Diamantopoulos PT,\nViniou NA. Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches. Front Oncol. 2021;11:722507. doi:10.3389\/fonc.2021.722507"}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/52\/3\/article-p137.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/52\/3\/article-p137.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/52\/3\/article-p137.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:14Z","timestamp":1760144234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/52\/3\/article-p137.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":52,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.17849\/insm-52-3-1-7.2","relation":{},"ISSN":["0743-6661"],"issn-type":[{"value":"0743-6661","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}